MedTrace Logo

Monocyte Activation in Preclinical Atherosclerosis

NCT02126280 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 170

Last updated 2014-04-30

No results posted yet for this study

Summary

The study of proinflammatory and anti-inflammatory cytokines and chemokines expression profiles in human monocytes to identify new effective biomarkers that have the best diagnostic potential in asymptomatic atherosclerosis.

Conditions

Interventions

OTHER

In vitro estimation of individual reactivity of monocytes

Technique for isolation/separation of monocytes with culture purity more than 95 % CD14-positive cells according to flow cytometry, the share of viable cells at least 98% by trypan blue vital staining, capable of producing TNFa at concentration of at least 50 pg/ml when stimulated with 100 ng/ml IFN-gamma, and CCL18 at concentration at least 30 pg/ml when stimulated with 10 ng/ml interleukin.

Sponsors & Collaborators

  • Institute for Atherosclerosis Research, Russia

    lead OTHER

Principal Investigators

  • Alexander N Orekhov, PhD, DSc · Institute for Atherosclerosis Research

Eligibility

Min Age
40 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02126280 on ClinicalTrials.gov